Non-secretory plasma cell myeloma

Summary

Non-secretory plasma cell myeloma (MONDO:0004817) is a cancer and 1 clinical trial. Top therapeutic interventions include carfilzomib. A subtype of plasma cell myeloma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-secretory plasma cell myeloma
Mondo ID	MONDO:0004817
DOID	DOID:9547
NCIT	C4734
SNOMED CT	277580004
UMLS	C3898125
MedGen	857719
GARD	0024113
Is cancer (heuristic)	yes

Also known as: non-secretory multiple myeloma · non-secretory plasma cell myeloma

Disease family

This is a subtype of plasma cell myeloma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › plasma cell myeloma › non-secretory plasma cell myeloma

Related subtypes (2): osteosclerotic plasma cell myeloma, smoldering plasma cell myeloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01301807	PHASE1	COMPLETED	Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARFILZOMIB	4	1
CHEMBL344227	0	1